Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Firebrick Pharma Limited ( (AU:FRE) ).
Firebrick Pharma has appointed seasoned pharmaceutical licensing executive Nilesh Wadhwa as Head of Business Development and Licensing, following an international search for a specialist to accelerate its partnering strategy. Wadhwa brings around three decades of experience in cross-border deals and market expansion across Asia-Pacific, the U.S. and Europe with major healthcare groups including Johnson & Johnson, Sanofi, Takeda and Alembic Pharmaceuticals.
Based in Australia from April 2026 after a transition period, Wadhwa will be tasked with driving approvals and licensing deals to lift Nasodine’s reach from three countries to as many as 10 while expanding the portfolio from two to four products. The move signals Firebrick’s intent to intensify its international push for Nasodine-branded povidone-iodine sprays, positioning the company for broader commercialisation and potentially enhancing long-term value for shareholders as it scales its presence in key growth markets.
The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.
More about Firebrick Pharma Limited
Firebrick Pharma Limited is an Australian pharmaceutical company focused on developing and commercialising novel formulations and uses of povidone-iodine. Its lead product, Nasodine Nasal Spray, is already available in the United States, Singapore and Fiji & South Pacific, with a follow-on Nasodine Throat Spray sold in Singapore and Fiji and plans for a broader Nasodine range targeting up to 10 markets.
Average Trading Volume: 66,940
Technical Sentiment Signal: Sell
Current Market Cap: A$13.89M
For a thorough assessment of FRE stock, go to TipRanks’ Stock Analysis page.